Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 197

1.

Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells.

Mitsutake N, Knauf JA, Mitsutake S, Mesa C Jr, Zhang L, Fagin JA.

Cancer Res. 2005 Mar 15;65(6):2465-73.

2.
3.

Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling.

Mesa C Jr, Mirza M, Mitsutake N, Sartor M, Medvedovic M, Tomlinson C, Knauf JA, Weber GF, Fagin JA.

Cancer Res. 2006 Jul 1;66(13):6521-9.

4.

Conditional expression of RET/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels.

Wang J, Knauf JA, Basu S, Puxeddu E, Kuroda H, Santoro M, Fusco A, Fagin JA.

Mol Endocrinol. 2003 Jul;17(7):1425-36. Epub 2003 Apr 10.

PMID:
12690093
5.

Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.

Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D, Fagin JA.

Clin Cancer Res. 2006 Mar 15;12(6):1785-93.

6.

BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications.

Tang KT, Lee CH.

J Chin Med Assoc. 2010 Mar;73(3):113-28. doi: 10.1016/S1726-4901(10)70025-3. Review.

7.

Clinical prognosis in BRAF-mutated PTC.

Puxeddu E, Moretti S.

Arq Bras Endocrinol Metabol. 2007 Jul;51(5):736-47. Review.

8.

BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.

Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, García-Rostán G.

Clin Endocrinol (Oxf). 2008 Apr;68(4):618-34. Epub 2007 Dec 5.

PMID:
18070147
9.

BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy.

Bommarito A, Richiusa P, Carissimi E, Pizzolanti G, Rodolico V, Zito G, Criscimanna A, Di Blasi F, Pitrone M, Zerilli M, Amato MC, Spinelli G, Carina V, Modica G, Latteri MA, Galluzzo A, Giordano C.

Endocr Relat Cancer. 2011 Nov 14;18(6):669-85. doi: 10.1530/ERC-11-0076. Print 2011 Dec.

10.

BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.

Romei C, Ciampi R, Faviana P, Agate L, Molinaro E, Bottici V, Basolo F, Miccoli P, Pacini F, Pinchera A, Elisei R.

Endocr Relat Cancer. 2008 Jun;15(2):511-20. doi: 10.1677/ERC-07-0130.

11.

BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.

Mitsutake N, Miyagishi M, Mitsutake S, Akeno N, Mesa C Jr, Knauf JA, Zhang L, Taira K, Fagin JA.

Endocrinology. 2006 Feb;147(2):1014-9. Epub 2005 Oct 27.

PMID:
16254036
12.

Thyrotropin signaling confers more aggressive features with higher genomic instability on BRAF(V600E)-induced thyroid tumors in a mouse model.

Orim F, Bychkov A, Shimamura M, Nakashima M, Ito M, Matsuse M, Kurashige T, Suzuki K, Saenko V, Nagayama Y, Yamashita S, Mitsutake N.

Thyroid. 2014 Mar;24(3):502-10. doi: 10.1089/thy.2013.0038. Epub 2014 Jan 15.

13.

Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.

Chakravarty D, Santos E, Ryder M, Knauf JA, Liao XH, West BL, Bollag G, Kolesnick R, Thin TH, Rosen N, Zanzonico P, Larson SM, Refetoff S, Ghossein R, Fagin JA.

J Clin Invest. 2011 Dec;121(12):4700-11. doi: 10.1172/JCI46382. Epub 2011 Nov 21.

14.

BRAF(V600E) mutation influences hypoxia-inducible factor-1alpha expression levels in papillary thyroid cancer.

Zerilli M, Zito G, Martorana A, Pitrone M, Cabibi D, Cappello F, Giordano C, Rodolico V.

Mod Pathol. 2010 Aug;23(8):1052-60. doi: 10.1038/modpathol.2010.86. Epub 2010 May 14.

15.

The Ca2+-calmodulin-dependent kinase II is activated in papillary thyroid carcinoma (PTC) and mediates cell proliferation stimulated by RET/PTC.

Rusciano MR, Salzano M, Monaco S, Sapio MR, Illario M, De Falco V, Santoro M, Campiglia P, Pastore L, Fenzi G, Rossi G, Vitale M.

Endocr Relat Cancer. 2010 Jan 29;17(1):113-23. doi: 10.1677/ERC-09-0214. Print 2010 Mar.

16.

Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas.

Kondo T, Nakazawa T, Murata S, Kurebayashi J, Ezzat S, Asa SL, Katoh R.

Hum Pathol. 2007 Dec;38(12):1810-8. Epub 2007 Aug 21.

PMID:
17714762
17.

Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.

Baitei EY, Zou M, Al-Mohanna F, Collison K, Alzahrani AS, Farid NR, Meyer B, Shi Y.

J Pathol. 2009 Apr;217(5):707-15. doi: 10.1002/path.2496.

PMID:
19156774
18.

Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma.

Koperek O, Kornauth C, Capper D, Berghoff AS, Asari R, Niederle B, von Deimling A, Birner P, Preusser M.

Am J Surg Pathol. 2012 Jun;36(6):844-50. doi: 10.1097/PAS.0b013e318246b527. Erratum in: Am J Surg Pathol. 2012 Oct;36(10):1578.

PMID:
22592144
19.

BRAF(V600E) mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas.

Durante C, Tallini G, Puxeddu E, Sponziello M, Moretti S, Ligorio C, Cavaliere A, Rhoden KJ, Verrienti A, Maranghi M, Giacomelli L, Russo D, Filetti S.

Eur J Endocrinol. 2011 Sep;165(3):455-63. doi: 10.1530/EJE-11-0283. Epub 2011 Jun 8.

20.

Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.

Preto A, Gonçalves J, Rebocho AP, Figueiredo J, Meireles AM, Rocha AS, Vasconcelos HM, Seca H, Seruca R, Soares P, Sobrinho-Simões M.

BMC Cancer. 2009 Oct 31;9:387. doi: 10.1186/1471-2407-9-387.

Items per page

Supplemental Content

Write to the Help Desk